120 Views

Collegium Pharmaceutical grabs $50 mln

Canton, Massachusetts-based Collegium Pharmaceutical Inc, a specialty pharmaceutical company focused on treating chronic pain, has secured $50 million in funding. TPG Biotech led the round with participation from RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management, Aperture Venture Partners, Longitude Capital, Skyline Ventures, Frazier Healthcare and Boston Millennia Partners. In conjunction with this financing, Dr. Eran Nadav, a partner and managing director at TPG Biotech, has been added to Collegium’s board of directors.

131 Views

Life sciences startup Unchained Labs grabs $25 mln

Pleasanton, California-based life sciences tools startup Unchained Labs has closed $25 million in Series A funding. Novo Ventures, Canaan Partners and TPG Biotech led the round. Also, the company has acquired Optim, a multiplex protein stability platform for biologics. No financial terms were disclosed.

117 Views

TPG Biotech backs Trevi Therapeutics

Trevi Therapeutics has raised $11 million in the final close of a $26 million Series B round. TPG Biotech, the life science investment arm of TPG, was the lead investor. Based in New Haven, Conn., Trevi is a biotech firm focused on developing Nalbuphine ER for chronic pruritus.

159 Views

Avidity NanoMedicines racks up $6 mln

Avidity NanoMedicines has secured $6 million in convertible note financing. Fidelity Biosciences and TPG Biotech co-led the round. Other investors included Brace Pharmaceuticals, Partner Fund Management and return backer Alethea Capital Management. In addition to the funding, Ben Auspitz from Fidelity Biosciences and Dr. Eran Nadav from TPG Biotech, will be added to Avidity’s board as observers. Based in La Jolla, Calif., Avidity is a maker of drugs that include antibody-siRNA complexes.

TPG Biotech leads Series B round for Trevi

Trevi Therapeutics said Wednesday that it has received $25 million in Series B financing. TPG Biotech, the life science venture investment arm of TPG, led the round. Based in New Haven, Conn., Trevo is a biotech firm focused on treating chronic pruritus conditions.

Otonomy scores $49 mln Series D funds

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

Epirus grabs $36 mln Series B funds and merges with Zalicus

Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that include Adage Capital, Greenwoods Investment, Gibralt US, Monashee Capital Partners, TPG Biotech, Montreux Equity Partners and 5AM Ventures. Also, Epirus will merge with Zalicus. No financial terms were disclosed. The merged entity will be led by Amit Munshi as president and CEO. Based in Boston, Epirus is a biopharmaceutical firm focused on biosimilar monoclonal antibodies while Zalicus specializes in developing new treatments for patients suffering from pain and inflammation.

DNAnexus secures $15 Million Series C

Cloud-based solutions provider DNAnexus has secured $15 million in Series C financing. The round was led by Claremont Creek Ventures, Google Ventures, TPG Biotech and First Round Capital.

Alphabet Energy Raises $16M From Encana, Claremont, TPG, CalCEF

Alphabet Energy Inc. said it raised $16 million in Series B financing. The round was led by Encana Corp. and joined by existing investors Claremont Creek Ventures, TPG Biotech and the CalCEF Clean Energy Angel Fund. The funding allows the company to speed up product development and launch its first product, a device that generates electricity from the exhaust flows of engines in industrial applications.

Auxogyn Raises $18 Million B Round

Auxogyn, the women’s reproductive health company based in Menlo Park, California, just raised $18 million in a Series B round led by SR One. All of its Series A investors, including Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures, participated in the funding. Simeon George, from SR One, and Nilesh Kumar, of […]

Alder BioPharma Bags $38M Round

Alder BioPharmaceuticals closed a $38 million Series D round led by a new investor—Novo Ventures—and including existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Novo’s Peter Bisgaard will join Alder’s board as part of the deal. Alder BioPharma is based in Washington and is develops products […]

Auxogyn Closes Series A at $20m

Auxogyn, a privately-held company focused on advancing women’s reproductive health, has closed the final tranche of its Series A financing, bringing total funding to $20 million. Investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures. PRESS RELEASE Auxogyn, Inc., a privately-held company focused on advancing women’s reproductive health, […]

Auxogyn Wraps Up Series A

Auxogyn Inc., a Menlo Park, Calif. company focusing on products for women’s reproductive health, has closed a final tranche for its Series A round. The company has now raised $20 million in total funding. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures, the company said in a statement.

Roka Closes Series D

Roka Bioscience has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates and TPG Biotech. Josh Bilenker, MD, partner at Aisling Capital, will join Roka’s board of directors. Upon completion of theround, the total amount raised since the company’s formation […]

Elevation Pharmaceuticals Closes $30M Series B

Elevation Pharmaceuticals Inc. said Wednesday that it had closed $30 million in Series B financing led by new investor Novo Ventures. The company, which develops aerosol therapy for patients living with chronic obstructive pulmonary disease, was also backed in the round by previous investors including Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners. As part of the deal, Novo Ventures’ Heath Lukatch joins the company’s board. Elevation is based in San Diego, Calif.

DNAnexus Adds $15M from Google Ventures, TPG Biotech

DNAnexus, a DNA data management and analysis platform, has closed a $15 million second round led by Google Ventures and TPG Biotech. First Round Capital, SoftTech VC, K9 Ventures, and Felicis Ventures also participated in the financing, which will be used for development. Krishna Yeshwant of Google Ventures, and Geoff Duyk of TPG Biotech, have joined the company’s board.

Elevation Pharma Inks $17 Million

San Diego-based Elevation Pharmaceuticals has drawn down a $17 million second tranche of its Series A financing. The biopharmaceutical company which develops new aerosol therapies for patients with respiratory diseases is celebrating positive results of a Phase 2a study and has initiated a Phase 2b study. All of the original participants in the Series A financing participated in the $17 million second tranche. These included Canaan Partners, Care Capital, TPG Biotech, and Mesa Verde Venture Partners.

PE HUB Community

Join the 12518 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget